GlassScriptPhysician profile
Katherine M Johnson
NPI 1487037594
$2,913.03
in general payments reported to CMS, 2019-2025
17 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,006 · 2022: $709 · 2023: $571 · 2024: $486 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,198.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,197.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $669.11 | 2021-2024 | Corevalve Evolut R |
| Astrazeneca Pharmaceuticals LP | $603.04 | 2021-2024 | Farxiga, Lokelma |
| Abbott Laboratories | $464.40 | 2021-2024 | Dragonfly Opstar, Navitor, Xience V |
| Boston Scientific Corporation | $220.96 | 2024-2025 | Avvigo Guidance System, Epic Vascular, Rotapro |
| Janssen Pharmaceuticals, INC | $153.12 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $131.25 | 2021-2025 | Lifevest |
| Edwards Lifesciences Corporation | $127.46 | 2021-2022 | |
| Pfizer INC. | $90.07 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $75.77 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $73.42 | 2022-2025 | |
| Abiomed | $70.17 | 2025 | |
| Shockwave Medical, INC | $62.59 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Amgen INC. | $56.57 | 2021-2023 | Repatha |
| Merck Sharp & Dohme LLC | $52.16 | 2022-2023 | Verquvo |
| Cardiva Medical, INC. | $25.28 | 2023 | Cardiva Vascade 6/7f Vcs |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.57 | 2023 | Jardiance |
| Chiesi USA, INC. | $18.09 | 2023 | Kengreal, Cleviprex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.